A Two-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Trial Profile

A Two-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Tozadenant (Primary)
  • Indications Liver disorders; Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors Biotie Therapies Corp.
  • Most Recent Events

    • 14 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top